Cargando…
Novel vaccines targeting dendritic cells by coupling allergoids to mannan
Allergen-specific immunotherapy (AIT) is the single disease-modifying treatment for allergy. Clinical trials show AIT to be safe and effective for many patients; however, it still faces problems related to efficacy, safety, long treatment duration and low patient adherence. There has been intensive...
Autores principales: | Benito-Villalvilla, Cristina, Soria, Irene, Subiza, José Luis, Palomares, Oscar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267119/ https://www.ncbi.nlm.nih.gov/pubmed/30546997 http://dx.doi.org/10.1007/s40629-018-0069-8 |
Ejemplares similares
-
Alum impairs tolerogenic properties induced by allergoid‐mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs
por: Benito‐Villalvilla, Cristina, et al.
Publicado: (2019) -
Structural studies of novel glycoconjugates from polymerized allergens (allergoids) and mannans as allergy vaccines
por: Manzano, Ana I., et al.
Publicado: (2015) -
Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice
por: Soria, I., et al.
Publicado: (2018) -
First‐in‐human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy
por: Nieto, Antonio, et al.
Publicado: (2022) -
A Combination of Polybacterial MV140 and Candida albicans V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections
por: Martin-Cruz, Leticia, et al.
Publicado: (2021)